EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort

Niyatee Samudra, D Luke Fischer, Steven Lenio, Argentina Lario Lago, Peter A Ljubenkov, Julio C Rojas, William W Seeley, Salvatore Spina, Adam M Staffaroni, Jonathan Tablante, Fattin Wekselman, Jennifer Lamoureux und 4 weitere

Alzheimer's & Dementia · 2024-05 · 20 (5) · 3334-3341

DOI: 10.1002/alz.13799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 27.03.2024. Verfasst von Niyatee Samudra und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: alpha-Synuclein, Lewy Body Disease, Autopsy, Sensitivity and Specificity. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institutes for Health, NIA NIH HHS, Rainwater Charity Foundation (L.V.), Alzheimer's Association (L.V.).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Lewy body disease (LBD) is a common primary or co‐pathology in neurodegenerative syndromes. An alpha‐synuclein seed amplification assay (αSyn‐SAA) is clinically available, but clinical performance, especially lower sensitivity in amygdala‐predominant cases, is not well understood. METHODS Antemortem CSF from neuropathology‐confirmed LBD cases was tested with αSyn‐SAA ( N = 56). Diagnostic performance and clinicopathological correlations were examined. RESULTS Similar to prior reports, sensitivity was 100% for diffuse and transitional LBD (9/9), and overall specificity was 96.3% (26/27). Sensitivity was lower in amygdala‐predominant (6/14, 42.8%) and brainstem‐predominant LBD (1/6, 16.7%), but early spread outside these regions (without meeting criteria for higher stage) was more common in αSyn‐SAA‐positive cases (6/7, 85.7%) than negative (2/13, 15.4%). DISCUSSION In this behavioral neurology cohort, αSyn‐SAA had excellent diagnostic performance for cortical LBD. In amygdala‐ and brainstem‐predominant cases, sensitivity was lower, but positivity was associated with anatomical spread, suggesting αSyn‐SAA detects early LBD progression in these cohorts. Highlights A cerebrospinal fluid alpha‐synuclein assay detects cortical LBD with high sensitivity/specificity. Positivity in prodromal stages of LBD was associated with early cortical spread. The assay provides precision diagnosis of LBD that could support clinical trials. The assay can also identify LBD co‐pathology, which may impact treatment responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinLewy Body DiseaseAutopsySensitivity and SpecificityHumansFemaleMaleAgedCohort StudiesAmygdalaAged, 80 and overBiomarkersMiddle Aged

Stichwörter der Autor:innen

Lewy body diseasealpha synucleincerebrospinal fluiddementia with Lewy bodiesseed amplification assay

Substanzen

alpha-SynucleinBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
  • Amprion Inc., San Diego, California, USA.
  • Department of Pathology, University of California, San Francisco, California, USA.

Förderung

  • National Institutes for Health
  • NIA NIH HHS
  • Rainwater Charity Foundation (L.V.), Alzheimer's Association (L.V.)
  • Shenandoah Fund (L.V., J.C.R.)
  • AlzOut (J.C.R.)
  • John Douglas French Alzheimer's Foundation (J.C.R.)

Zitieren

APA

Samudra, N., Fischer, D. L., Lenio, S., Lario Lago, A., Ljubenkov, P. A., Rojas, J. C., Seeley, W. W., Spina, S., Staffaroni, A. M., Tablante, J., Wekselman, F., Lamoureux, J., Concha-Marambio, L., Grinberg, L. T., Boxer, A. L., & VandeVrede, L. (2024). Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort. Alzheimer's & Dementia, 20(5), 3334-3341. https://doi.org/10.1002/alz.13799

Vancouver

Samudra N, Fischer DL, Lenio S, Lario Lago A, Ljubenkov PA, Rojas JC, et al. Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort. Alzheimer's & Dementia. 2024;20(5):3334-3341. doi:10.1002/alz.13799

BibTeX
@article{Samudra2024,
  author = {Samudra, Niyatee and Fischer, D Luke and Lenio, Steven and Lario Lago, Argentina and Ljubenkov, Peter A and Rojas, Julio C and Seeley, William W and Spina, Salvatore and Staffaroni, Adam M and Tablante, Jonathan and Wekselman, Fattin and Lamoureux, Jennifer and Concha-Marambio, Luis and Grinberg, Lea T and Boxer, Adam L and VandeVrede, Lawren},
  title = {Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {5},
  pages = {3334--3341},
  doi = {10.1002/alz.13799}
}
Kostenlos starten →